FOLFIRINOX + NIS793 in Pancreatic Cancer

This is a two part Phase 1B study investigating whether NIS793 improves the clinical benefit of FOLFIRINOX treatment for metastatic pancreas adenocarcinoma.The first part is a safety run-in using a dose escalation strategy to determine the recommended phase 2 dose of the drug NIS793. In the second part participants will be a randomized assigned to receive either FOLFIRINOX plus NIS793 or FOLFIRINOX alone. NIS793 binds to the protein that can be found on tumor cells, called TGFβ, thereby preventing its role in cancer metastasis (spreading). FOLFIRINOX is a combination of 4 chemotherapy drugs that may help shrink tumors. The U.S. Food and Drug Administration (FDA) has not approved NIS793 as a treatment for any disease. The FDA has approved FOLFIRINOX as a treatment option for metastatic pancreas adenocarcinoma The FDA has not approved the combination of NIS793 and FOLFIRINOX as a treatment for any disease. The research study procedures include screening for eligibility and study treatment including evaluations and follow up visits. It is expected that about 50 people will take part in this research study. Novartis, a pharmaceutical company, is supporting this research study by providing funding for the study, including the study drug.